KR20210060555A - Src 호몰로지-2 포스파타아제 억제제로서의 융합된 삼환식 고리 유도체 - Google Patents
Src 호몰로지-2 포스파타아제 억제제로서의 융합된 삼환식 고리 유도체 Download PDFInfo
- Publication number
- KR20210060555A KR20210060555A KR1020217011212A KR20217011212A KR20210060555A KR 20210060555 A KR20210060555 A KR 20210060555A KR 1020217011212 A KR1020217011212 A KR 1020217011212A KR 20217011212 A KR20217011212 A KR 20217011212A KR 20210060555 A KR20210060555 A KR 20210060555A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- amino
- alkyl
- pyrido
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCCC1(C)C*(C)(CC2CC)CC2=*CCC1 Chemical compound CCCCC1(C)C*(C)(CC2CC)CC2=*CCC1 0.000 description 16
- OIBRHNUGJRDNJV-LZDTVADOSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@@H](C4)OC5COC5)N4c3ncc2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@@H](C4)OC5COC5)N4c3ncc2)[C@@H]1N OIBRHNUGJRDNJV-LZDTVADOSA-N 0.000 description 2
- SWAMKYFFWIXMGW-QMMMGPOBSA-N C1CN2c3ncccc3OC[C@@H]2C1 Chemical compound C1CN2c3ncccc3OC[C@@H]2C1 SWAMKYFFWIXMGW-QMMMGPOBSA-N 0.000 description 1
- VLIYZNPSKHJQHM-NXEZZACHSA-N C=Cc1c2OC[C@@H](C[C@H](C3)F)N3c2ncc1 Chemical compound C=Cc1c2OC[C@@H](C[C@H](C3)F)N3c2ncc1 VLIYZNPSKHJQHM-NXEZZACHSA-N 0.000 description 1
- YSILWLDKWQYILK-UHFFFAOYSA-N CC(C(CC1)(CCN1C(OC(C)(C)C)=O)C(OC)=O)O Chemical compound CC(C(CC1)(CCN1C(OC(C)(C)C)=O)C(OC)=O)O YSILWLDKWQYILK-UHFFFAOYSA-N 0.000 description 1
- BZEGBADCJMBYCL-NSHDSACASA-N CC(C)(C)OC(N1[C@H](COc2cccnc2F)CCC1)=O Chemical compound CC(C)(C)OC(N1[C@H](COc2cccnc2F)CCC1)=O BZEGBADCJMBYCL-NSHDSACASA-N 0.000 description 1
- CHILYMULOZHNNM-PIJUOVFKSA-N CC(C)N(CC1)CCC1(CC(C)C1)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CC(C)C1)[C@@H]1N CHILYMULOZHNNM-PIJUOVFKSA-N 0.000 description 1
- OXFCYCANYAYOPP-SNVBAGLBSA-N CC(C)N(CC1)CCC1(CC(C1)(F)F)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CC(C1)(F)F)[C@@H]1N OXFCYCANYAYOPP-SNVBAGLBSA-N 0.000 description 1
- WUOSGIBDNCCVSA-RRKGBCIJSA-N CC(C)N(CC1)CCC1(CC(C1)F)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CC(C1)F)[C@@H]1N WUOSGIBDNCCVSA-RRKGBCIJSA-N 0.000 description 1
- OVSRJIHTCNCDJI-PIJUOVFKSA-N CC(C)N(CC1)CCC1(CC(C1)OC)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CC(C1)OC)[C@@H]1N OVSRJIHTCNCDJI-PIJUOVFKSA-N 0.000 description 1
- AQKAYWCIBZKJHJ-LLVKDONJSA-N CC(C)N(CC1)CCC1(CCC1)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CCC1)[C@@H]1N AQKAYWCIBZKJHJ-LLVKDONJSA-N 0.000 description 1
- RWPXAPXHHGUINV-RRKGBCIJSA-N CC(C)N(CC1)CCC1(CCC1F)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CCC1F)[C@@H]1N RWPXAPXHHGUINV-RRKGBCIJSA-N 0.000 description 1
- FIIQNBHGZTWXNH-SNVBAGLBSA-N CC(C)N(CC1)CCC1(COC1)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(COC1)[C@@H]1N FIIQNBHGZTWXNH-SNVBAGLBSA-N 0.000 description 1
- RFDNCOAJKLFFCX-WDEREUQCSA-N CC(C)N(CC1)CCC1(CO[C@H]1C)[C@@H]1N Chemical compound CC(C)N(CC1)CCC1(CO[C@H]1C)[C@@H]1N RFDNCOAJKLFFCX-WDEREUQCSA-N 0.000 description 1
- HSAYSVPWFXXGBC-ICWAXCMMSA-N CC(C)N(CC1)CCC1([C@@H](C(C)C1)N)/C1=C/C Chemical compound CC(C)N(CC1)CCC1([C@@H](C(C)C1)N)/C1=C/C HSAYSVPWFXXGBC-ICWAXCMMSA-N 0.000 description 1
- PLZHJDNUAAZAOA-GLGOKHISSA-N CC(C)N(CC1)CCC1([C@@H](C(C)C1)N)C1=C Chemical compound CC(C)N(CC1)CCC1([C@@H](C(C)C1)N)C1=C PLZHJDNUAAZAOA-GLGOKHISSA-N 0.000 description 1
- KKGNBGCZRLQURJ-YKAQBRKTSA-N CC(C)N(CC1)CCC1([C@@H](CC1)N)/C1=C/C Chemical compound CC(C)N(CC1)CCC1([C@@H](CC1)N)/C1=C/C KKGNBGCZRLQURJ-YKAQBRKTSA-N 0.000 description 1
- USZJKZYZRJASLI-GFCCVEGCSA-N CC(C)N(CC1)CCC1([C@@H](CC1)N)C1=C Chemical compound CC(C)N(CC1)CCC1([C@@H](CC1)N)C1=C USZJKZYZRJASLI-GFCCVEGCSA-N 0.000 description 1
- OMCALEABJJWJLJ-UHFFFAOYSA-N CC(C)c1c2OCC(CCC3)N3c2ncc1 Chemical compound CC(C)c1c2OCC(CCC3)N3c2ncc1 OMCALEABJJWJLJ-UHFFFAOYSA-N 0.000 description 1
- ZANWSNIPVIVSQC-NXEZZACHSA-N CC(C)c1c2OC[C@@H](C[C@H](C3)O)N3c2ncc1 Chemical compound CC(C)c1c2OC[C@@H](C[C@H](C3)O)N3c2ncc1 ZANWSNIPVIVSQC-NXEZZACHSA-N 0.000 description 1
- OMCALEABJJWJLJ-SNVBAGLBSA-N CC(C)c1ccnc2c1OC[C@@H]1N2CCC1 Chemical compound CC(C)c1ccnc2c1OC[C@@H]1N2CCC1 OMCALEABJJWJLJ-SNVBAGLBSA-N 0.000 description 1
- XCLHQVURWYUOEU-AWEZNQCLSA-N CC(C)c1ccnc2c1OC[C@@]1(C)N2CCC1 Chemical compound CC(C)c1ccnc2c1OC[C@@]1(C)N2CCC1 XCLHQVURWYUOEU-AWEZNQCLSA-N 0.000 description 1
- VIUDGTRGFPSMSC-DNILWPGESA-N CC1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OCC(C2)N3CC2F)[C@@H]1N Chemical compound CC1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OCC(C2)N3CC2F)[C@@H]1N VIUDGTRGFPSMSC-DNILWPGESA-N 0.000 description 1
- DDDRLRFWBVLUNJ-PIJUOVFKSA-N CCC1OCC(CC2)(CCN2C(C)C)[C@@H]1N Chemical compound CCC1OCC(CC2)(CCN2C(C)C)[C@@H]1N DDDRLRFWBVLUNJ-PIJUOVFKSA-N 0.000 description 1
- RQNTZIJZCBEJFA-PIJUOVFKSA-N CCCc1c2OCC(C[C@H](C3)OC)N3c2ncc1 Chemical compound CCCc1c2OCC(C[C@H](C3)OC)N3c2ncc1 RQNTZIJZCBEJFA-PIJUOVFKSA-N 0.000 description 1
- KIVYWBQSLUZTQT-UHFFFAOYSA-N CCN(C1)c2nccc(I)c2OC1O Chemical compound CCN(C1)c2nccc(I)c2OC1O KIVYWBQSLUZTQT-UHFFFAOYSA-N 0.000 description 1
- WGLFPQAJJBTOGF-UHFFFAOYSA-N CCc1c2OCC(CC(C3)(F)F)N3c2ncc1 Chemical compound CCc1c2OCC(CC(C3)(F)F)N3c2ncc1 WGLFPQAJJBTOGF-UHFFFAOYSA-N 0.000 description 1
- WTEOACFUOCGCAC-UHFFFAOYSA-N COC1CN2c3nccc(S)c3OCC2C1 Chemical compound COC1CN2c3nccc(S)c3OCC2C1 WTEOACFUOCGCAC-UHFFFAOYSA-N 0.000 description 1
- HRJHTUCFWBVALR-ZGNVVGTOSA-N COCC1CN2c(nccc3Sc4ncc(N(CC5)CCC5(Cc5c6cccn5)[C@@H]6N)nc4)c3OC[C@@H]2C1 Chemical compound COCC1CN2c(nccc3Sc4ncc(N(CC5)CCC5(Cc5c6cccn5)[C@@H]6N)nc4)c3OC[C@@H]2C1 HRJHTUCFWBVALR-ZGNVVGTOSA-N 0.000 description 1
- PAKOJENWJZRWER-GWFQSRPTSA-N COCOCC1CN2c(nccc3Sc4ncc(N(CC5)CCC5(Cc5c6cccn5)[C@@H]6N)nc4)c3OC[C@@H]2C1 Chemical compound COCOCC1CN2c(nccc3Sc4ncc(N(CC5)CCC5(Cc5c6cccn5)[C@@H]6N)nc4)c3OC[C@@H]2C1 PAKOJENWJZRWER-GWFQSRPTSA-N 0.000 description 1
- XJLXOJYZSRNWGR-IUCAKERBSA-N COCO[C@@H]1CN2c(nccc3I)c3OC[C@@H]2C1 Chemical compound COCO[C@@H]1CN2c(nccc3I)c3OC[C@@H]2C1 XJLXOJYZSRNWGR-IUCAKERBSA-N 0.000 description 1
- GSIICDXSWZABMG-IUCAKERBSA-N COC[C@@H]1CN2c(nccc3B(O)O)c3OC[C@@H]2C1 Chemical compound COC[C@@H]1CN2c(nccc3B(O)O)c3OC[C@@H]2C1 GSIICDXSWZABMG-IUCAKERBSA-N 0.000 description 1
- GHBLKRGJLJRKBB-DGUDUIIESA-N COC[C@@H]1CN2c(nccc3Sc4nc(CO)c(N(CC5)CCC5(COC56CCC5)[C@@H]6N)nc4)c3OC[C@@H]2C1 Chemical compound COC[C@@H]1CN2c(nccc3Sc4nc(CO)c(N(CC5)CCC5(COC56CCC5)[C@@H]6N)nc4)c3OC[C@@H]2C1 GHBLKRGJLJRKBB-DGUDUIIESA-N 0.000 description 1
- RSDCCDXIKHNEEC-CNRYDXITSA-N C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=O)=NC=C2Sc2c3OC[C@H](CC(COC)C4)N4c3ncc2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2C(N(C)C2=O)=NC=C2Sc2c3OC[C@H](CC(COC)C4)N4c3ncc2)[C@@H]1N RSDCCDXIKHNEEC-CNRYDXITSA-N 0.000 description 1
- IGSGJEYNZCLOAG-CKJXQJPGSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](COCC4)N4c3ncc2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](COCC4)N4c3ncc2)[C@@H]1N IGSGJEYNZCLOAG-CKJXQJPGSA-N 0.000 description 1
- RBMNCCZKEIJSCP-GSRZOBFVSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@@H](C4)F)N4c3ncc2)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@@H](C4)F)N4c3ncc2)[C@@H]1NC(OC(C)(C)C)=O RBMNCCZKEIJSCP-GSRZOBFVSA-N 0.000 description 1
- GPMCVSXTDRZSLO-VCAMNPENSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@@H](C4)OC(N)=O)N4c3ncc2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@@H](C4)OC(N)=O)N4c3ncc2)[C@@H]1N GPMCVSXTDRZSLO-VCAMNPENSA-N 0.000 description 1
- WRYBCDHGKKPMKW-MBEBEXRASA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@H](COCC4COC4)C4)N4c3ncc2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2c3OC[C@H](C[C@H](COCC4COC4)C4)N4c3ncc2)[C@@H]1N WRYBCDHGKKPMKW-MBEBEXRASA-N 0.000 description 1
- FQXAGRFLFFENPB-VTBIZFIGSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OCC(C2)N3CCS2(=O)=O)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OCC(C2)N3CCS2(=O)=O)[C@@H]1N FQXAGRFLFFENPB-VTBIZFIGSA-N 0.000 description 1
- HDHKHQYESCRVMC-VTBIZFIGSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OCC2N3CCC2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OCC2N3CCC2)[C@@H]1N HDHKHQYESCRVMC-VTBIZFIGSA-N 0.000 description 1
- YQNLXVRRERHINB-OQHPUSGOSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@@H]2N3CC(COCOC)C2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@@H]2N3CC(COCOC)C2)[C@@H]1N YQNLXVRRERHINB-OQHPUSGOSA-N 0.000 description 1
- GPMCVSXTDRZSLO-GXYOHSSGSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@@H]2OC(N)=O)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@@H]2OC(N)=O)[C@@H]1N GPMCVSXTDRZSLO-GXYOHSSGSA-N 0.000 description 1
- JZIVZJLOIQOPCM-PPELCYSXSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@@]2(C)O)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@@]2(C)O)[C@@H]1N JZIVZJLOIQOPCM-PPELCYSXSA-N 0.000 description 1
- RCRWPBKEEYEBDV-DVSDUFGPSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2C#N)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2C#N)[C@@H]1N RCRWPBKEEYEBDV-DVSDUFGPSA-N 0.000 description 1
- VIUDGTRGFPSMSC-VCAMNPENSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2F)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2F)[C@@H]1N VIUDGTRGFPSMSC-VCAMNPENSA-N 0.000 description 1
- VQWMDPOJXWOEDJ-NRNPOHGYSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2OC)C1NC(OC(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2OC)C1NC(OC(C)(C)C)=O VQWMDPOJXWOEDJ-NRNPOHGYSA-N 0.000 description 1
- AZCZIDVDHVGBES-ACTFIFLWSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2OC)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2OC)[C@@H]1N AZCZIDVDHVGBES-ACTFIFLWSA-N 0.000 description 1
- VXXRNTLTIAEVNE-ACTFIFLWSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2S(C)(=O)=O)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@H]2S(C)(=O)=O)[C@@H]1N VXXRNTLTIAEVNE-ACTFIFLWSA-N 0.000 description 1
- JZIVZJLOIQOPCM-UDBZMMNRSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@]2(C)O)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)c(CO)nc2Sc2ccnc3c2OC[C@H](C2)N3C[C@]2(C)O)[C@@H]1N JZIVZJLOIQOPCM-UDBZMMNRSA-N 0.000 description 1
- LJZPRAULMDMOHN-GSRZOBFVSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2)cnc2Sc2ccnc3c2OC[C@H]2N3C[C@@H](COCOC)C2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2)cnc2Sc2ccnc3c2OC[C@H]2N3C[C@@H](COCOC)C2)[C@@H]1N LJZPRAULMDMOHN-GSRZOBFVSA-N 0.000 description 1
- PVRKROKBYOCJNE-XHPYRIGBSA-N C[C@@H]1OCC(CC2)(CCN2c(nc2N)cnc2Sc2ccnc3c2OC[C@H]2N3CC(COC)C2)[C@@H]1N Chemical compound C[C@@H]1OCC(CC2)(CCN2c(nc2N)cnc2Sc2ccnc3c2OC[C@H]2N3CC(COC)C2)[C@@H]1N PVRKROKBYOCJNE-XHPYRIGBSA-N 0.000 description 1
- GJXGUOHXCPBCCM-HJJDGDTKSA-N C[C@@H]1OCC(CC2)(CCN2c2ncc(-c3c4OC[C@H](C[C@H](COC)C5)N5c4ncc3)nc2CO)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@@H]1OCC(CC2)(CCN2c2ncc(-c3c4OC[C@H](C[C@H](COC)C5)N5c4ncc3)nc2CO)[C@@H]1NC(OC(C)(C)C)=O GJXGUOHXCPBCCM-HJJDGDTKSA-N 0.000 description 1
- MVNRYXUORSUNOP-GFCCVEGCSA-N C[C@]1(CCC2)N2c2nccc(C)c2OC1 Chemical compound C[C@]1(CCC2)N2c2nccc(C)c2OC1 MVNRYXUORSUNOP-GFCCVEGCSA-N 0.000 description 1
- FYBXDLCZVCGOHX-SECBINFHSA-N Cc1ccnc2c1OC[C@@H]1N2CCC1 Chemical compound Cc1ccnc2c1OC[C@@H]1N2CCC1 FYBXDLCZVCGOHX-SECBINFHSA-N 0.000 description 1
- FSXXWCJSQXXZGW-UHFFFAOYSA-N Fc1ncccc1OCC1NCCC1 Chemical compound Fc1ncccc1OCC1NCCC1 FSXXWCJSQXXZGW-UHFFFAOYSA-N 0.000 description 1
- JAAKTIIIKVBDFM-SNVBAGLBSA-N N[C@H](COC1)C1(CC1)CCN1c(c(CO)n1)ncc1Br Chemical compound N[C@H](COC1)C1(CC1)CCN1c(c(CO)n1)ncc1Br JAAKTIIIKVBDFM-SNVBAGLBSA-N 0.000 description 1
- GPPQUXXKLHOWCB-UHFFFAOYSA-N O=S(CC1)(CC2N1c1nccc(I)c1OC2)=O Chemical compound O=S(CC1)(CC2N1c1nccc(I)c1OC2)=O GPPQUXXKLHOWCB-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- CGBSWCOIPWWGHT-UHFFFAOYSA-N OCC(C1)NCCS1(=O)=O Chemical compound OCC(C1)NCCS1(=O)=O CGBSWCOIPWWGHT-UHFFFAOYSA-N 0.000 description 1
- UEQRKEWMEMJXQO-UHFFFAOYSA-N Oc1cccnc1F Chemical compound Oc1cccnc1F UEQRKEWMEMJXQO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733061P | 2018-09-18 | 2018-09-18 | |
| US62/733,061 | 2018-09-18 | ||
| US201862749655P | 2018-10-23 | 2018-10-23 | |
| US62/749,655 | 2018-10-23 | ||
| US201962810911P | 2019-02-26 | 2019-02-26 | |
| US62/810,911 | 2019-02-26 | ||
| US201962883121P | 2019-08-06 | 2019-08-06 | |
| US201962883120P | 2019-08-06 | 2019-08-06 | |
| US62/883,120 | 2019-08-06 | ||
| US62/883,121 | 2019-08-06 | ||
| PCT/US2019/051592 WO2020061103A1 (en) | 2018-09-18 | 2019-09-17 | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210060555A true KR20210060555A (ko) | 2021-05-26 |
Family
ID=68084982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011212A Pending KR20210060555A (ko) | 2018-09-18 | 2019-09-17 | Src 호몰로지-2 포스파타아제 억제제로서의 융합된 삼환식 고리 유도체 |
| KR1020217011213A Active KR102834408B1 (ko) | 2018-09-18 | 2019-09-17 | Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217011213A Active KR102834408B1 (ko) | 2018-09-18 | 2019-09-17 | Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US11459340B2 (https=) |
| EP (2) | EP3853234B1 (https=) |
| JP (2) | JP7337174B2 (https=) |
| KR (2) | KR20210060555A (https=) |
| CN (2) | CN112996795B (https=) |
| AU (2) | AU2019344899B2 (https=) |
| BR (1) | BR112021005082A2 (https=) |
| CA (2) | CA3113234A1 (https=) |
| CL (1) | CL2021000628A1 (https=) |
| CO (1) | CO2021004436A2 (https=) |
| CR (1) | CR20210175A (https=) |
| DK (1) | DK3853234T3 (https=) |
| ES (1) | ES3036496T3 (https=) |
| FI (1) | FI3853234T3 (https=) |
| MX (1) | MX2021003158A (https=) |
| PH (1) | PH12021550604A1 (https=) |
| PL (1) | PL3853234T3 (https=) |
| PT (1) | PT3853234T (https=) |
| SA (1) | SA521421505B1 (https=) |
| SG (1) | SG11202102679QA (https=) |
| TW (1) | TWI827677B (https=) |
| WO (2) | WO2020061103A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| TW201930292A (zh) * | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| AU2019240299B2 (en) | 2018-03-21 | 2023-06-22 | D.E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020156243A1 (zh) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| WO2021043077A1 (zh) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
| CN114502165A (zh) * | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| MX2022003454A (es) | 2019-09-24 | 2022-04-19 | Relay Therapeutics Inc | Inhibidores de fosfatasa shp2 y metodos para su fabricacion y uso. |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| JP2023530838A (ja) * | 2020-06-22 | 2023-07-20 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用 |
| WO2022042331A1 (zh) * | 2020-08-25 | 2022-03-03 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| CA3201612A1 (en) * | 2020-12-11 | 2022-06-16 | Leenus MARTIN | Combination therapies for the treatment of cancer |
| JP2023553532A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| CN117098537A (zh) * | 2020-12-11 | 2023-11-21 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| JP2023553533A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| CN117120449A (zh) * | 2020-12-11 | 2023-11-24 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| TW202241907A (zh) * | 2020-12-18 | 2022-11-01 | 美商瑞佛路森醫藥公司 | 製備shp2抑制劑之方法 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN116848121A (zh) * | 2020-12-18 | 2023-10-03 | 建新公司 | 制备shp2抑制剂的方法 |
| WO2022206684A1 (zh) * | 2021-03-31 | 2022-10-06 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| US20240285624A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| IL309401A (en) * | 2021-06-24 | 2024-02-01 | Erasca Inc | Combined treatment with ERK1/2 and SHP2 inhibitors |
| TW202319056A (zh) * | 2021-07-09 | 2023-05-16 | 南韓商治納輔醫藥科技有限公司 | Ｓｈｐ２抑制劑及其用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| WO2023044065A1 (en) * | 2021-09-17 | 2023-03-23 | Erasca, Inc. | Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20260055121A1 (en) * | 2022-08-24 | 2026-02-26 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2024148307A1 (en) * | 2023-01-06 | 2024-07-11 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (385)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62206545A (ja) | 1986-03-07 | 1987-09-11 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| GB8729614D0 (en) | 1987-12-18 | 1988-02-03 | Beecham Group Plc | Novel compounds |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5360459A (en) | 1991-05-13 | 1994-11-01 | The Lubrizol Corporation | Copper-containing organometallic complexes and concentrates and diesel fuels containing same |
| JPH05196976A (ja) | 1991-11-18 | 1993-08-06 | Toshiba Corp | 有機非線形光学材料 |
| JPH05181221A (ja) | 1991-12-27 | 1993-07-23 | Konica Corp | ハロゲン化銀写真感光材料 |
| GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
| FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AU3785597A (en) | 1996-08-14 | 1998-03-06 | Takeda Chemical Industries Ltd. | Cyclic urea compounds, their production and use as herbicides |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6117973A (en) | 1997-02-24 | 2000-09-12 | Georgia Tech Research Corp. | PNA monomers with electron donor or acceptor |
| FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP2000072695A (ja) | 1998-08-24 | 2000-03-07 | Sumitomo Pharmaceut Co Ltd | 環状化合物 |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| WO2000076984A2 (en) | 1999-05-21 | 2000-12-21 | Biovitrum Ab | Novel compounds, their use and preparation |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| BR0012984A (pt) | 1999-08-04 | 2002-07-16 | Millennium Pharm Inc | Método para tratar um estado associado com o mc4-r em um mamìfero, composto de ligação ao mc4-r, e, composição farmacêutica |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| NZ517788A (en) | 1999-09-28 | 2003-11-28 | Eisai Co Ltd | Quinuclidine compounds and drugs containing the same as the active ingredient |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| JP4548761B2 (ja) | 2000-06-15 | 2010-09-22 | 富士フイルムホールディングス株式会社 | 潤滑剤組成物 |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10032633A1 (de) | 2000-07-05 | 2002-01-17 | Bayer Ag | Verfahren zum Auffinden von Hemmstoffen der Protoporphyrinogen-Oxidase |
| JP2002122954A (ja) | 2000-08-08 | 2002-04-26 | Fuji Photo Film Co Ltd | 感光性ハロゲン化銀写真乳剤、これを含有するハロゲン化銀写真感光材料および感光性ハロゲン化銀写真乳剤の感度向上方法 |
| WO2002015910A1 (en) | 2000-08-18 | 2002-02-28 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
| AU2001294865A1 (en) | 2000-09-30 | 2002-04-15 | Loctite | Low shrinkage thermosetting resin compositions and methods of use therefor |
| US6963001B2 (en) | 2000-09-30 | 2005-11-08 | Henkel Corporation | Low shrinkage thermosetting resin compositions and methods of use therefor |
| AU2002213467A8 (en) | 2000-10-11 | 2009-07-30 | Chemocentryx Inc | Modulation of ccr4 function |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| SE0103646D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic chroman compounds |
| KR20080079341A (ko) | 2001-01-16 | 2008-08-29 | 아스트라제네카 아베 | 치료용 헤테로시클릭 화합물 |
| JP2004517129A (ja) | 2001-01-16 | 2004-06-10 | アストラゼネカ・アクチエボラーグ | 治療用クロモン化合物 |
| JP3616628B2 (ja) | 2001-03-01 | 2005-02-02 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物 |
| ATE438615T1 (de) | 2001-04-06 | 2009-08-15 | Biocryst Pharm Inc | Biarylverbindungen als serinproteaseinhibitoren |
| WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
| WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| CN100430052C (zh) | 2002-03-05 | 2008-11-05 | 默克弗罗斯特加拿大有限公司 | 组织蛋白酶半胱氨酸蛋白酶抑制剂 |
| US20050247001A1 (en) | 2002-03-15 | 2005-11-10 | Nuevolution A/S | Building block forming a c-c or a c-hetero atom bond uponreaction |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| AU2003265663A1 (en) | 2002-08-23 | 2004-03-11 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| RU2366655C2 (ru) | 2003-03-14 | 2009-09-10 | Оно Фармасьютикал Ко., Лтд. | Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента |
| GB0306430D0 (en) | 2003-03-20 | 2003-04-23 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalysts |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| WO2004101529A1 (ja) | 2003-05-19 | 2004-11-25 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| JP4231379B2 (ja) | 2003-10-15 | 2009-02-25 | 富士フイルム株式会社 | 潤滑剤組成物 |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| DE10355066A1 (de) | 2003-11-25 | 2005-06-23 | Basf Ag | Verfahren zur asymmetrischen Synthese |
| US7632946B2 (en) | 2004-02-06 | 2009-12-15 | Abbott Laboratories | Naphthyridine-based antibacterial compositions |
| JP4829506B2 (ja) | 2004-02-17 | 2011-12-07 | 石原産業株式会社 | チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
| EP1595888A1 (en) | 2004-05-11 | 2005-11-16 | Degussa AG | Cycloolefin phosphine ligands and their use in catalysis |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| GB0415879D0 (en) | 2004-07-15 | 2004-08-18 | Bp Chem Int Ltd | Polymerisation catalyst |
| GB0418022D0 (en) | 2004-08-12 | 2004-09-15 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalyst |
| ES2377430T3 (es) | 2004-09-02 | 2012-03-27 | Genentech, Inc. | Inhibidores piridílicos de la señalización de hedgehog |
| GB0420396D0 (en) | 2004-09-14 | 2004-10-13 | Bp Chem Int Ltd | Polyolefins |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| GB2436261B (en) | 2004-12-11 | 2010-06-09 | Merck Patent Gmbh | Liquid crystal compounds,liquid crystal medium and liquid crystal display |
| JP2008527030A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| JP4749000B2 (ja) | 2005-02-22 | 2011-08-17 | 富士フイルム株式会社 | グリース組成物 |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| EP1867704B1 (en) | 2005-03-15 | 2010-09-15 | FUJIFILM Corporation | Surface treatment method using disc-like compound, (lubricating) composition for surface treatment, and surface-treated article |
| US20060156481A1 (en) | 2005-03-22 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| US20070260062A1 (en) | 2005-03-31 | 2007-11-08 | Goetz Frederick J | Heterocyclical Chromophore Architectures with Novel Electronic Acceptor Systems |
| ZA200709817B (en) | 2005-04-21 | 2009-02-25 | Serono Lab | 2,3 substituted pyrazine sulfonmides as inhibitors of CRTH2 |
| WO2006114180A1 (de) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| WO2006119800A1 (en) | 2005-05-09 | 2006-11-16 | Technische Universität Braunschweig | Light emitting compound for electroluminescent applications |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| TW200726764A (en) | 2005-06-27 | 2007-07-16 | Bristol Myers Squibb Co | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
| WO2007011721A1 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| JP2007056213A (ja) | 2005-08-26 | 2007-03-08 | Fujifilm Corp | 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材 |
| DK1940821T3 (da) | 2005-10-19 | 2013-06-10 | Gruenenthal Gmbh | Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler. |
| FR2892859B1 (fr) | 2005-10-27 | 2008-06-06 | Commissariat Energie Atomique | Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications |
| CA2630920A1 (en) | 2005-11-22 | 2007-05-31 | University Of South Florida | Inhibition of cell proliferation |
| WO2007064869A2 (en) | 2005-12-01 | 2007-06-07 | Yale University | Catalysts for aryl sulfide synthesis and method of producing aryl sulfides |
| JP2008007634A (ja) | 2006-06-29 | 2008-01-17 | Fujifilm Corp | 潤滑剤組成物 |
| EP2061466A4 (en) | 2006-08-23 | 2010-12-29 | Xtl Biopharmaceuticals Ltd | 4-THIO-SUBSTITUTED CHINOLINE AND NAPHTHYRIDEIN COMPOUNDS |
| JP5606736B2 (ja) | 2006-09-02 | 2014-10-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 反応性メソゲンを配向するための粒子ビーム法 |
| WO2008118626A2 (en) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibitors of jnk and methods for identifying inhibitors of jnk |
| US7956020B2 (en) | 2007-03-29 | 2011-06-07 | Fujifilm Corporation | Lubricant composition, mechanical element, and method for producing triazine derivatives |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| TWI519508B (zh) | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
| US8063165B2 (en) | 2007-06-18 | 2011-11-22 | Bridgestone Corporation | Functional polymers prepared with sulfur-containing initiators |
| JP2009013314A (ja) | 2007-07-06 | 2009-01-22 | Toyo Ink Mfg Co Ltd | 光硬化型インキ |
| EP2195656A4 (en) | 2007-08-21 | 2011-10-19 | Senomyx Inc | HUMAN T2R BITTERITY RECEPTORS AND USES THEREOF |
| US8143276B2 (en) | 2007-08-22 | 2012-03-27 | Xtl Biopharmaceuticals Ltd. | 4-thio substituted quinoline and naphthyridine compounds |
| WO2009030318A1 (de) | 2007-08-29 | 2009-03-12 | Merck Patent Gmbh | Flüssigkristallanzeige |
| ES2593279T3 (es) | 2007-08-29 | 2016-12-07 | Methylgene Inc. | Procesos e intermedios para preparar inhibidores de cinasa heterocíclicos condensados |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5580201B2 (ja) | 2007-10-08 | 2014-08-27 | アドビヌス・セラピューティクス・プライベート・リミテッド | グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用 |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| CN101918389A (zh) | 2007-11-02 | 2010-12-15 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| WO2009078813A1 (en) | 2007-12-19 | 2009-06-25 | Nanyang Technological University | Method of forming oseltamivir and derivatives thereof |
| EP2098226A1 (de) | 2008-03-06 | 2009-09-09 | Forschungsverbund Berlin e.V. | AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| KR101612577B1 (ko) | 2008-07-28 | 2016-04-14 | 메르크 파텐트 게엠베하 | 액정 디스플레이 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US8545720B2 (en) | 2008-12-22 | 2013-10-01 | Merck Patent Gmbh | Liquid-crystal display |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| DE102010006691A1 (de) | 2009-02-06 | 2010-10-28 | Merck Patent Gmbh | Flüssigkristallines Medium und Flüssigkristallanzeige |
| US20120077959A1 (en) | 2009-02-16 | 2012-03-29 | Zhang X Peter | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate |
| US20120040977A1 (en) | 2009-02-23 | 2012-02-16 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| JP2010217692A (ja) | 2009-03-18 | 2010-09-30 | Konica Minolta Holdings Inc | 表示素子 |
| NZ595674A (en) | 2009-04-02 | 2012-12-21 | Ct Nac Investigaciones Oncologicas Cnio | Imidazo[2,1-b][1,3,4]thiadiazole derivatives |
| US20120059179A1 (en) | 2009-04-03 | 2012-03-08 | The Scripps Research Insitiute | Palladium-catalyzed ortho-fluorination |
| DE102010012900A1 (de) | 2009-04-23 | 2010-11-25 | Merck Patent Gmbh | Flüssigkristallanzeige |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| WO2011005355A1 (en) | 2009-05-07 | 2011-01-13 | Achaogen, Inc. | Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria |
| WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| WO2010147975A1 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| WO2010147973A1 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| WO2010148422A1 (en) | 2009-06-25 | 2010-12-29 | Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for treating parasitic infestations |
| WO2011022502A1 (en) | 2009-08-18 | 2011-02-24 | Georgetown University | Boronic acid compositions and methods related to cancer |
| JP5728683B2 (ja) | 2009-09-04 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン |
| EP2292720A1 (en) | 2009-09-08 | 2011-03-09 | Merck Patent GmbH | Liquid-crystal display |
| US8877930B2 (en) | 2009-11-04 | 2014-11-04 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| KR20110088098A (ko) | 2010-01-28 | 2011-08-03 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| PH12012501662A1 (en) | 2010-02-18 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Triazolo [4,5 - b] pyridin derivatives |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| KR20110101444A (ko) | 2010-03-08 | 2011-09-16 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 포함하는 유기 발광 소자 |
| KR20110104765A (ko) | 2010-03-17 | 2011-09-23 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| PE20130774A1 (es) | 2010-07-29 | 2013-06-26 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de ampk y metodos para emplearlos |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012020357A1 (en) | 2010-08-09 | 2012-02-16 | Advinus Therapeutics Ltd. | Acetamide compounds, their process and pharmaceutical application |
| AU2011291034A1 (en) | 2010-08-20 | 2013-03-14 | Grünenthal GmbH | Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor |
| US9463256B2 (en) | 2010-10-14 | 2016-10-11 | Koninklijke Philips N.V. | Pretargeting kit, method and agents used therein |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| CA2815543A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-heterocyclic carbene complexes, their preparation and use |
| US20120108819A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-Heterocyclic Carbene Complexes, Their Preparation And Use |
| KR20120045905A (ko) | 2010-11-01 | 2012-05-09 | 한국화학연구원 | 헤테로고리 축합된 피리도 화합물 및 이의 제조방법 |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| JP5992435B2 (ja) | 2010-12-21 | 2016-09-14 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 循環からの生体分子の除去剤 |
| US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
| JP5618815B2 (ja) | 2010-12-24 | 2014-11-05 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、並びに、この組成物を用いた感活性光線性又は感放射線性膜及びパターン形成方法 |
| WO2012092471A2 (en) | 2010-12-29 | 2012-07-05 | Development Center For Biotechnology | Novel tubulin inhibitors and methods of using the same |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| EP2681196B1 (en) | 2011-03-04 | 2015-09-09 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
| DE102012003796A1 (de) | 2011-03-18 | 2012-09-20 | Merck Patent Gmbh | Flüssigkristallines Medium |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN103459554B (zh) | 2011-03-29 | 2018-07-10 | 默克专利股份有限公司 | 液晶介质 |
| US20140163229A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| EP2522369A1 (en) | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| CA2836338C (en) | 2011-05-16 | 2022-05-03 | Koninklijke Philips N.V. | Tetrazine derivatives used in bio-orthogonal drug activation |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| JP5782836B2 (ja) | 2011-05-27 | 2015-09-24 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置、照明装置、並びに化合物 |
| HK1197066A1 (zh) | 2011-06-03 | 2015-01-02 | Massachusetts Institute Of Technology | Z選擇性關環複分解反應 |
| KR20140063579A (ko) | 2011-06-28 | 2014-05-27 | 메르크 파텐트 게엠베하 | 유기 반도체로서의 인다세노 유도체 |
| WO2013004372A1 (en) | 2011-07-07 | 2013-01-10 | Merck Patent Gmbh | Liquid-crystalline medium |
| KR20140068009A (ko) | 2011-07-08 | 2014-06-05 | 메르크 파텐트 게엠베하 | 공액 중합체 |
| CN108484449A (zh) | 2011-09-09 | 2018-09-04 | 蓝瑟斯医学影像公司 | 用于合成和使用显像剂的组合物、方法和系统 |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| EP2615083A1 (en) | 2012-01-10 | 2013-07-17 | Studiengesellschaft Kohle mbH | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
| JP5814141B2 (ja) | 2012-01-23 | 2015-11-17 | ユー・ディー・シー アイルランド リミテッド | 合成法、その合成法を用いて合成された化合物および有機電界発光素子 |
| CN104136576B (zh) | 2012-02-22 | 2020-10-16 | 默克专利股份有限公司 | 液晶介质 |
| EP2834313A1 (en) | 2012-04-03 | 2015-02-11 | 3M Innovative Properties Company | Crosslinkable composition comprising photobase generators |
| AU2013251109B2 (en) | 2012-04-20 | 2017-08-24 | Bayer Cropscience Ag | N-cycloalkyl-N-[(heterocyclylphenyl)methylene]-(thio)carboxamide derivatives |
| FR2992317B1 (fr) | 2012-06-22 | 2016-05-13 | Diverchim | Procede de preparation de peptides chiraux |
| US8575283B1 (en) | 2012-06-28 | 2013-11-05 | Formosa Plastics Corporation, U.S.A. | Heterocyclic organic compounds as electron donors for polyolefin catalysts |
| WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| WO2014036897A1 (zh) | 2012-09-04 | 2014-03-13 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
| JPWO2014068893A1 (ja) | 2012-10-29 | 2016-09-08 | コニカミノルタ株式会社 | 位相差フィルム、円偏光板、及び画像表示装置 |
| WO2014078702A1 (en) | 2012-11-16 | 2014-05-22 | Basf Se | Lubricant compositions comprising epoxide compounds to improve fluoropolymer seal compatibility |
| JP2016500076A (ja) * | 2012-11-20 | 2016-01-07 | プリンシピア バイオファーマ インコーポレイテッド | Ｊａｋ３阻害剤としてのアザインドール誘導体 |
| FI2922574T3 (fi) | 2012-11-22 | 2023-08-11 | Tagworks Pharmaceuticals B V | Kemiallisesti pilkkoutuva ryhmä |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| US20150297741A1 (en) | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| US9580653B2 (en) | 2012-12-12 | 2017-02-28 | Merck Patent Gmbh | Liquid-crystalline medium |
| JP6335428B2 (ja) | 2012-12-21 | 2018-05-30 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| WO2014106524A2 (de) | 2013-01-03 | 2014-07-10 | Merck Patent Gmbh | Materialien für elektronische vorrichtungen |
| WO2014122933A1 (ja) | 2013-02-08 | 2014-08-14 | ソニー株式会社 | 有機エレクトロルミネッセンス素子 |
| CN105263910A (zh) | 2013-02-18 | 2016-01-20 | 斯克利普斯研究所 | 具有治疗潜力的血管加压素受体调节剂 |
| WO2014134127A1 (en) | 2013-02-26 | 2014-09-04 | Northeastern University | Cannabinergic nitrate esters and related analogs |
| US9487472B2 (en) | 2013-02-26 | 2016-11-08 | President And Fellows Of Harvard College | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| US9290528B1 (en) | 2013-03-15 | 2016-03-22 | University Of Kentucky Research Foundation | Light-activated compounds |
| JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
| EP2981522A4 (en) | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| CN105102581A (zh) | 2013-04-08 | 2015-11-25 | 默克专利有限公司 | 有机电致发光器件 |
| JP6567498B2 (ja) | 2013-04-08 | 2019-08-28 | メルク パテント ゲーエムベーハー | 熱活性化遅延蛍光材料をもつ有機エレクトロルミネッセント素子 |
| CA2944198C (en) | 2013-04-26 | 2021-11-16 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) |
| JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
| WO2015003137A1 (en) | 2013-07-03 | 2015-01-08 | University Of Connecticut | Polymerization of diene monomers |
| WO2015003094A2 (en) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| KR102252761B1 (ko) | 2013-08-02 | 2021-05-18 | 메르크 파텐트 게엠베하 | 액정 매질 |
| WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
| EP2857405A1 (en) | 2013-10-01 | 2015-04-08 | Studiengesellschaft Kohle mbH | Process for the trans-selective hydroboration of internal alkynes |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| JP6088995B2 (ja) | 2013-10-24 | 2017-03-01 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6522313B2 (ja) | 2013-10-24 | 2019-05-29 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| KR101537860B1 (ko) | 2013-11-22 | 2015-07-20 | 롯데케미칼 주식회사 | 내감마선 성능이 향상된 폴리카보네이트 수지 조성물 및 이를 이용한 성형품 |
| JP6215674B2 (ja) | 2013-11-29 | 2017-10-18 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6309834B2 (ja) | 2013-12-11 | 2018-04-11 | 株式会社Adeka | 着色性組成物 |
| JP2015163671A (ja) | 2013-12-13 | 2015-09-10 | 株式会社Adeka | ラジカル重合性組成物 |
| KR20150070027A (ko) | 2013-12-16 | 2015-06-24 | 메르크 파텐트 게엠베하 | 액정 매질 |
| US10020455B2 (en) | 2014-01-07 | 2018-07-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate platinum and palladium complex emitters containing phenyl-pyrazole and its analogues |
| US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| KR20150091942A (ko) | 2014-02-04 | 2015-08-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| JP6313604B2 (ja) | 2014-02-05 | 2018-04-18 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、感活性光線性又は感放射線性膜、感活性光線性又は感放射線性膜を備えたマスクブランクス、パターン形成方法、及び電子デバイスの製造方法 |
| CA2936886A1 (en) | 2014-02-27 | 2015-08-03 | Merck Patent Gmbh | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| CA2941716A1 (en) | 2014-03-07 | 2015-09-11 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| HUE053939T2 (hu) | 2014-05-13 | 2021-08-30 | Hoffmann La Roche | Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk |
| MX389718B (es) | 2014-05-16 | 2025-03-20 | Olaplex Inc | Formulaciones y metodos de tratamiento con queratina. |
| CA2949511A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
| CN106573907B (zh) | 2014-06-05 | 2020-09-08 | 默克专利有限公司 | 喹啉衍生物及其用于神经退化性疾病的用途 |
| US20170174826A1 (en) | 2014-07-16 | 2017-06-22 | Agency For Science, Technology And Research | Donor-acceptor polymers |
| US9818959B2 (en) | 2014-07-29 | 2017-11-14 | Arizona Board of Regents on behlaf of Arizona State University | Metal-assisted delayed fluorescent emitters containing tridentate ligands |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
| EP3188271B1 (en) | 2014-08-26 | 2022-05-04 | Idemitsu Kosan Co., Ltd | Organic electroluminescent element and electronic device |
| HUE064081T2 (hu) | 2014-08-28 | 2024-02-28 | Samsung Electronics Co Ltd | Kompozit elektrolit és az ezt tartalmazó lítium akkumulátor |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| EP3230279A1 (en) | 2014-12-10 | 2017-10-18 | Massachusetts Institute of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| KR102384224B1 (ko) | 2014-12-30 | 2022-04-08 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| WO2016145383A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, University Of Texas System | Mth1 inhibitors for treating disease |
| KR102434696B1 (ko) | 2015-03-13 | 2022-08-22 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| AR104555A1 (es) | 2015-05-07 | 2017-07-26 | Bristol Myers Squibb Co | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg |
| US9458308B1 (en) | 2015-05-12 | 2016-10-04 | Lotte Chemical Corporation | Polycarbonate resin composition with increased gamma-radiation resistant property and molded article using the same |
| US9879039B2 (en) | 2015-06-03 | 2018-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues |
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| FR3037952B1 (fr) | 2015-06-24 | 2019-01-25 | Compagnie Generale Des Etablissements Michelin | Procede de synthese d'oximes aromatiques |
| EP3112440B1 (en) | 2015-07-02 | 2019-07-24 | Merck Patent GmbH | Liquid-crystal medium |
| WO2017015562A1 (en) | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| GB201514015D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And Dept Of Health And Human Services | Novel pyridazinones and their use in the treatment of cancer |
| GB201514018D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic | Novel tricyclic compounds and their use in the treatment of cancer |
| US10201531B2 (en) | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| EP3133078B1 (en) | 2015-08-18 | 2019-01-30 | Samsung Electronics Co., Ltd. | Organometallic compound and organic light-emitting device including the same |
| KR101796227B1 (ko) | 2015-08-21 | 2017-11-10 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10240085B2 (en) | 2015-08-27 | 2019-03-26 | Samsung Electronics Co., Ltd. | Thin film and organic light-emitting device including the same |
| KR102542465B1 (ko) | 2015-09-22 | 2023-06-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| SE541053C2 (sv) | 2015-09-30 | 2019-03-19 | Epiroc Rock Drills Ab | System och förfarande för borrplansgenerering, borrigg, datorprogram samt datorprogramprodukt |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| EP3162875B1 (en) | 2015-10-30 | 2018-05-23 | Merck Patent GmbH | Polymerisable compounds and the use thereof in liquid-crystal displays |
| JP6859358B2 (ja) | 2015-11-02 | 2021-04-14 | ゲナーゼ セラピューティクス ベー．フェー．Ｇｅｎａｓｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｂ．Ｖ． | テトラヒドロインダゾール及びその医学的使用 |
| KR20180081596A (ko) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| KR20170069342A (ko) | 2015-12-10 | 2017-06-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CN106892924B (zh) | 2015-12-17 | 2021-01-08 | 四川科伦博泰生物医药股份有限公司 | 短效苯并二氮*衍生物、其制备方法及其用途 |
| KR102579752B1 (ko) | 2015-12-22 | 2023-09-19 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR20170075118A (ko) | 2015-12-22 | 2017-07-03 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10336772B2 (en) | 2015-12-28 | 2019-07-02 | Samsung Electronics Co., Ltd. | Bicarbazole compound, material for organic light-emitting device including bicarbazole compound, and organic light-emitting device including bicarbazole compound |
| KR102419178B1 (ko) | 2015-12-29 | 2022-07-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102396293B1 (ko) | 2015-12-29 | 2022-05-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2017117239A1 (en) | 2015-12-30 | 2017-07-06 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
| EP3190164B1 (en) | 2016-01-05 | 2019-07-24 | Samsung Electronics Co., Ltd | Composition, thin film including the composition, and organic light-emitting device including the composition or the thin film |
| KR102633852B1 (ko) | 2016-01-25 | 2024-02-07 | 삼성디스플레이 주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
| JP6987064B2 (ja) | 2016-02-08 | 2021-12-22 | ハー・ルンドベック・アクチエゼルスカベット | １−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの合成 |
| KR102628850B1 (ko) | 2016-03-07 | 2024-01-25 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| CA3015817A1 (en) | 2016-03-09 | 2017-09-14 | President And Fellows Of Harvard College | Direct palladium-catalyzed aromatic fluorination |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| JP7059009B2 (ja) | 2016-03-31 | 2022-04-25 | 株式会社Ｄｎｐファインケミカル | 感光性着色樹脂組成物、カラーフィルタ及びその製造方法、並びに表示装置 |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102642199B1 (ko) | 2016-04-07 | 2024-03-05 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| MX388576B (es) * | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| KR102666178B1 (ko) | 2016-06-07 | 2024-05-14 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN109661228A (zh) | 2016-06-20 | 2019-04-19 | 库拉肿瘤学公司 | 用erk抑制剂治疗鳞状细胞癌 |
| US20180002604A1 (en) | 2016-06-30 | 2018-01-04 | Merck Patent Gmbh | Liquid-crystalline medium |
| EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| US11299673B2 (en) | 2016-08-12 | 2022-04-12 | Merck Patent Gmbh | Liquid-crystal medium |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| KR102721990B1 (ko) | 2016-08-16 | 2024-10-29 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| EA038219B1 (ru) | 2016-08-19 | 2021-07-26 | Арена Фармасьютикалз, Инк. | Агонисты рецептора 5-ht2c и композиции, а также способ их применения |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| CN109790468B (zh) | 2016-09-28 | 2023-06-13 | 默克专利股份有限公司 | 可聚合的液晶材料及经聚合的液晶膜 |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US11424410B2 (en) | 2016-09-29 | 2022-08-23 | Sumitomo Chemical Company, Limited | Light emitting device |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| KR102506326B1 (ko) | 2016-10-13 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Ror 감마 조정제로서의 헤테로시클릭 술폰 |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| AR110152A1 (es) | 2016-11-09 | 2019-02-27 | Bristol Myers Squibb Co | SULFONAS TRICÍCLICAS COMO MODULADORES DE RORg |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP2020507625A (ja) | 2017-02-07 | 2020-03-12 | オブリーク セラピューティクス アーベー | ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用 |
| AU2018218521C1 (en) | 2017-02-07 | 2022-06-09 | Oblique Therapeutics Ab | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR102395784B1 (ko) | 2017-03-27 | 2022-05-10 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| KR102461719B1 (ko) | 2017-05-23 | 2022-11-01 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| JP6907312B2 (ja) | 2017-06-14 | 2021-07-21 | 富士フイルム株式会社 | 組成物、膜、レンズ、固体撮像素子、化合物 |
| KR20180137311A (ko) | 2017-06-16 | 2018-12-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| US20200123115A1 (en) | 2017-06-26 | 2020-04-23 | Esteve Pharmaceuticals, S.A. | Compounds having multimodal activity against pain |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| KR20190014187A (ko) | 2017-07-27 | 2019-02-12 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함하는 유기 발광 소자 |
| GB201712110D0 (en) | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| JP7346015B2 (ja) | 2017-09-06 | 2023-09-19 | 住友化学株式会社 | 発光素子 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP7447002B2 (ja) | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| KR102526756B1 (ko) | 2017-09-29 | 2023-04-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| KR20200062261A (ko) | 2017-09-29 | 2020-06-03 | 메르크 파텐트 게엠베하 | 중합성 화합물 및 이의 액정 디스플레이에서의 용도 |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| KR102518722B1 (ko) | 2017-11-21 | 2023-04-07 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| US11584763B2 (en) | 2017-12-22 | 2023-02-21 | Hibercell, Inc. | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| US11572370B2 (en) | 2018-01-08 | 2023-02-07 | Biohaven Therapeutics Ltd. | CD16A binding agents and uses thereof |
| KR102595918B1 (ko) | 2018-01-18 | 2023-11-14 | 삼성디스플레이 주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 상기 유기 발광 소자를 포함한 유기 발광 장치 |
| CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
| CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
| KR102824606B1 (ko) | 2018-02-13 | 2025-06-25 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 표시 장치 |
| JP7335882B2 (ja) | 2018-02-13 | 2023-08-30 | ブルーレイ セラピューティクス （シャンハイ） カンパニー，リミティド | ピリミジン縮合環式化合物及びその製造方法、並びに使用 |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| IL276232B2 (en) | 2018-03-02 | 2024-04-01 | Otsuka Pharma Co Ltd | Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases |
| US12520712B2 (en) | 2018-03-08 | 2026-01-06 | Samsung Display Co., Ltd. | Organic light-emitting device |
| US11004918B2 (en) | 2018-03-09 | 2021-05-11 | Samsung Display Co., Ltd. | Electronic apparatus |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| AU2019240299B2 (en) | 2018-03-21 | 2023-06-22 | D.E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| CN108794485B (zh) | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类toll样受体调节剂、其药物组合物、制备方法与用途 |
| MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
| CN110492006B (zh) | 2018-05-14 | 2020-06-12 | 江苏三月光电科技有限公司 | 一种基于含硼有机化合物的电致发光器件 |
| CN108840886A (zh) | 2018-06-22 | 2018-11-20 | 南京工业大学 | 一种铂配合物蓝光材料以及有机发光器件 |
| MX2021000795A (es) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| CN108863982B (zh) | 2018-08-04 | 2022-02-01 | 南昌航空大学 | 一种吩噻嗪/吩恶嗪类化合物的有机电合成方法 |
| US11518770B2 (en) | 2018-08-06 | 2022-12-06 | Purdue Research Foundation | Sesquiterpenoid analogs |
| CN112601750B (zh) | 2018-08-10 | 2023-10-31 | 纳维尔制药有限公司 | Ptpn11（shp2）抑制剂 |
| CR20210175A (es) * | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| JP2022508651A (ja) | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ，インコーポレイテッド | 癌を処置するためのｓｈｐ２阻害剤組成物および方法 |
-
2019
- 2019-09-17 CR CR20210175A patent/CR20210175A/es unknown
- 2019-09-17 CA CA3113234A patent/CA3113234A1/en active Pending
- 2019-09-17 PL PL19779687.3T patent/PL3853234T3/pl unknown
- 2019-09-17 ES ES19779687T patent/ES3036496T3/es active Active
- 2019-09-17 JP JP2021539487A patent/JP7337174B2/ja active Active
- 2019-09-17 US US17/277,293 patent/US11459340B2/en active Active
- 2019-09-17 KR KR1020217011212A patent/KR20210060555A/ko active Pending
- 2019-09-17 WO PCT/US2019/051592 patent/WO2020061103A1/en not_active Ceased
- 2019-09-17 SG SG11202102679QA patent/SG11202102679QA/en unknown
- 2019-09-17 CN CN201980074211.0A patent/CN112996795B/zh active Active
- 2019-09-17 AU AU2019344899A patent/AU2019344899B2/en active Active
- 2019-09-17 EP EP19779687.3A patent/EP3853234B1/en active Active
- 2019-09-17 TW TW108133442A patent/TWI827677B/zh active
- 2019-09-17 US US16/573,900 patent/US20200115389A1/en not_active Abandoned
- 2019-09-17 CN CN201980074583.3A patent/CN113227103B/zh active Active
- 2019-09-17 BR BR112021005082-5A patent/BR112021005082A2/pt unknown
- 2019-09-17 DK DK19779687.3T patent/DK3853234T3/da active
- 2019-09-17 MX MX2021003158A patent/MX2021003158A/es unknown
- 2019-09-17 FI FIEP19779687.3T patent/FI3853234T3/fi active
- 2019-09-17 WO PCT/US2019/051590 patent/WO2020061101A1/en not_active Ceased
- 2019-09-17 KR KR1020217011213A patent/KR102834408B1/ko active Active
- 2019-09-17 PT PT197796873T patent/PT3853234T/pt unknown
- 2019-09-17 EP EP19779686.5A patent/EP3853233A1/en not_active Withdrawn
- 2019-09-17 CA CA3113233A patent/CA3113233A1/en active Pending
- 2019-09-17 AU AU2019344897A patent/AU2019344897B2/en active Active
- 2019-09-17 JP JP2021539488A patent/JP7542538B2/ja active Active
-
2020
- 2020-05-12 US US15/930,309 patent/US10894797B2/en active Active
- 2020-09-18 US US17/025,790 patent/US11518772B2/en active Active
- 2020-10-19 US US17/074,337 patent/US11034705B2/en active Active
-
2021
- 2021-03-15 CL CL2021000628A patent/CL2021000628A1/es unknown
- 2021-03-17 SA SA521421505A patent/SA521421505B1/ar unknown
- 2021-03-17 PH PH12021550604A patent/PH12021550604A1/en unknown
- 2021-04-09 CO CONC2021/0004436A patent/CO2021004436A2/es unknown
-
2022
- 2022-11-01 US US18/051,679 patent/US12264167B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12264167B2 (en) | Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors | |
| US20250018049A1 (en) | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway | |
| US20240287100A1 (en) | Alkylidene derivatives as kras inhibitors | |
| WO2024091409A1 (en) | Tricyclic derivatives as kras inhibitors | |
| WO2023249970A1 (en) | Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| EP4543889A1 (en) | Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| WO2023250029A1 (en) | Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| WO2022015670A1 (en) | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors | |
| EA044940B1 (ru) | Производные конденсированного трициклического кольца в качестве ингибиторов фосфатазы с доменом гомологии src2 | |
| WO2025212828A1 (en) | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway | |
| WO2025137391A1 (en) | Bifunctional compounds containing pyrido[2,3-d]pyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 4 via ubiquitin proteasome pathway | |
| WO2025117981A1 (en) | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| WO2025240536A1 (en) | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway | |
| WO2025137385A1 (en) | Bifunctional compounds containing pyrido[2,3-d]p¥rimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 and cyclin- dependent kinase 4 via ubiquitin proteasome pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |